[ad_1] Merck & Co. Inc.’s Januvia brand medication, used to treat Type 2 diabetes. Daniel Acker | Bloomberg | Getty Images Medicare is poised to directly negotiate drug prices with the pharmaceutical industry this fall for the first time in the program’s nearly six-decade history. The Centers for Medicare and Medicaid Services will unveil, no…
[ad_1] In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter in Los Angeles, April 17, 2023. Mario Tama | Getty Images The European Union’s drug regulator on Tuesday said it has broadened an investigation into the risk of suicidal thoughts and self-injury among patients taking Novo Nordisk‘s Ozempic, Wegovy…
[ad_1] Chief Executive Officers of pharmaceutical companies testify before the Senate Finance Committee on “Drug Pricing in America: A Prescription for Change, Part II” February 26, 2019 in Washington, DC. From left to right are Richard A. Gonzalez, chairman and CEO of AbbVie Inc; Pascal Soriot, executive director and CEO of AstraZeneca; Giovanni Caforio, chairman…
[ad_1] Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world’s biggest cancer research conference in Chicago, starting Thursday. Investors have already caught a glimpse of the topics that will be discussed but many are eager to hear the details behind the abstracts, and no doubt…
[ad_1] Robert Galbraith | Reuters Horizon Therapeutics expects its $27.8 billion sale to Amgen to close as early as the end of the third quarter, earlier than previously planned — if the Federal Trade Commission’s attempt to block the deal fails — according to a document filed Thursday with the Securities and Exchange Commission. The…
[ad_1] A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange, July 29, 2019. Brendan McDermid | Reuters Pfizer plans to raise $31 billion through a debt offering to fund its proposed acquisition of cancer drug maker Seagen, for what would be its largest takeover since 2009,…
[ad_1] The Federal Trade Commission on Tuesday filed a lawsuit seeking to block drug giant Amgen‘s $27.8 billion acquisition of Horizon Therapeutics, arguing that the deal would “stifle competition” in the pharmaceutical industry. The FTC said that the deal would allow Amgen to “entrench the monopoly positions” of two of Horizon’s fast-growing medications: the thyroid…
[ad_1] (L-R) Richard A. Gonzalez, chairman and CEO of AbbVie Inc., Pascal Soriot, executive director and CEO of AstraZeneca, Giovanni Caforio, chairman of the board and CEO of Bristol-Myers Squibb Co., Jennifer Taubert, executive vice president and worldwide chairman of Janssen Pharmaceuticals, Johnson & Johnson, Kenneth C. Frazier, chairman and CEO of Merck & Co….
[ad_1] While there has been plenty of buzz about how successful patients have been in losing weight while taking a new class of obesity medications, there is a growing realization that when people stop taking these pricey drugs, the pounds can creep back on. There was a frank discussion of this on Eli Lilly’s first-quarter…
